Research Topics
| Kathy PritchardSummaryAffiliation: Sunnybrook and Women's College Health Sciences Centre Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Selection of adjuvant chemotherapy for treatment of node-positive breast cancerMaureen Trudeau
Division of Medical Oncology and Haematology, Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, Canada
Lancet Oncol 6:886-98. 2005....- HER2 and responsiveness of breast cancer to adjuvant chemotherapyKathleen I Pritchard
Toronto Sunnybrook Regional Cancer Centre and the University of Toronto, Toronto, ON, Canada
N Engl J Med 354:2103-11. 2006.... - Adjuvant endocrine therapies for pre-/perimenopausal womenKathleen I Pritchard
Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ont, Canada M4N 3M5
Breast 14:547-54. 2005..The presence of these steroid hormone receptors remains the most useful predictive factor in selecting therapy for breast cancer... - Clinical trial update: National Cancer Institute of CanadaKathy Pritchard
Toronto Sunnybrook Regional Cancer Centre
Breast Cancer Res 7:48-51. 2005..The Group has also fostered, together with the NCIC CTG Investigational New Drug (IND) Program, a series of phase II and phase I/II studies which will be carried through if possible, into the phase III setting... - Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal womenKathleen Pritchard
Breast Cancer Site Group, Toronto Sunnybrook Regional Cancer Centre, Canada
Breast Cancer Res 7:70-6. 2005..Adjuvant aromatase inhibitors should not be used in premenopausal women... - The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studiesK I Pritchard
Division of Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Center, 2075 Bayview Avenue, North York, Ont, Canada M4N 3M5
Breast 15:S14-20. 2006..However, results from the Zometa-Femara adjuvant synergy trial (Z-FAST) suggest that zoledronic acid, when used concomitantly with letrozole, is able to manage bone loss in postmenopausal women with early breast cancer... - Cardiovascular health and aromatase inhibitorsKathleen I Pritchard
Toronto Sunnybrook Regional Cancer Centre, Sunnybrook Health Sciences Centre, and the University of Toronto, Toronto, Ontario, Canada
Drugs 66:1727-40. 2006..Moreover, physicians should assess cardiovascular risk, and monitor and treat patients already diagnosed with or at risk for coronary heart disease, according to established guidelines... - Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging systemHarriette J Kahn
Department of Pathology, Sunnybrook and Women s College Health Sciences Center, Toronto, Ontario, Canada
Breast J 12:294-301. 2006..This information is important with regard to the practice of sentinel node biopsy and subsequent axillary node dissection and to the decision to administer adjuvant therapy based on detection of micrometastases in lymph nodes... - Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17Edith A Perez
St Michael s Hospital, Toronto, Canada
J Clin Oncol 24:3629-35. 2006..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen... - Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Breast Cancer Res Treat 99:295-300. 2006..CONCLUSION: These analyses suggest that, at least out to about 48 months, longer duration of letrozole treatment is associated with greater benefit in the extended adjuvant therapy setting... - Managing patients on endocrine therapy: focus on quality-of-life issuesTimothy J Whelan
McMaster University, Hamilton, Ontario, Canada
Clin Cancer Res 12:1056s-1060s. 2006..However, clinical benefits of these agents are generally achieved without major detrimental effect on overall QOL... - Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statementSteven E Come
Breast Cancer Program, Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Clin Cancer Res 12:997s-1000s. 2006 - Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist careEva Grunfeld
Cancer Outcomes Research Program, Cancer Care Nova Scotia and Dalhousie University, Halifax, Nova Scotia
J Clin Oncol 24:848-55. 2006..It is usual practice for routine follow-up to take place in specialist clinics. This study tested the hypothesis that follow-up by the patient's family physician is a safe and acceptable alternative to specialist follow-up... - Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysisJudith Anne W Chapman
Department of Public Health Sciences, Faculty of Medicine, University of Toronto, and Department of Laboratory Medicine and Pathology, St Michael s Hospital, Toronto, Ontario, Canada
Breast J 12:37-47. 2006..Estimated prognoses may differ substantially by survival analysis model type, by amounts that might affect patient management, and we think that the log-normal model has a major advantage over the Cox model for survival analysis... - Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemiaJames R Wright
Juravinski Cancer Center at Hamilton Health Sciences, Hamilton, Ontario, Canada
J Clin Oncol 25:1027-32. 2007..We designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic patients with advanced non-small-cell carcinoma of the lung (NSCLC)... - Adjuvant therapy for breast cancer: we are solving the puzzle, but pieces are still missingKathleen I Pritchard
J Natl Cancer Inst 99:494-5. 2007 - Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss
Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
J Clin Oncol 25:2006-11. 2007..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status... - Antihormone therapy in recurrent metastatic breast cancerKathleen I Pritchard
JAMA 299:2745; author reply 2745. 2008 - Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss
Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
J Clin Oncol 26:1948-55. 2008..When the trial was unblinded, patients who received placebo (PLAC) were offered LET... - Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17Hyman B Muss
University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
J Clin Oncol 26:1956-64. 2008..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women... - Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic reviewAndrea Eisen
Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5
Cancer Treat Rev 34:157-74. 2008.... - Combining endocrine agents with chemotherapy: which patients and what sequence?Kathleen I Pritchard
Clinical Trials and Epidemiology, University of Toronto at Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
Cancer 112:718-22. 2008..Considering the demonstrated importance of the timing of chemotherapy and tamoxifen in the postmenopausal setting, these questions should be explored further... - Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge ConferenceSteven E Come
Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Cancer 112:673-8. 2008..All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer... - Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trialsFederica Cuppone
Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
Cancer 112:260-7. 2008..0] was demonstrated... - Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16Michael Crump
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
J Clin Oncol 26:37-43. 2008.... - Adjuvant therapy of the very young womanKathleen I Pritchard
Toronto Sunnybrook Regional Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Canada M4N 3M5
Breast 16:S136-46. 2007..In the future more sophisticated molecular factors may identify those who require hormones alone, chemotherapy alone, newer biologic therapies, or combinations of these approaches... - Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertainNan Soon Wong
J Clin Oncol 25:3787. 2007 - Triple-negative breast cancer: clinical features and patterns of recurrenceRebecca Dent
Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
Clin Cancer Res 13:4429-34. 2007..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer... - HER2/neu in systemic therapy for women with breast cancer: a systematic reviewBindi Dhesy-Thind
Juravinski Cancer Centre, Hamilton, ON, Canada
Breast Cancer Res Treat 109:209-29. 2008..Many studies have suggested that this gene may be associated with the relative efficacy of chemotherapy and endocrine therapy options... - Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP systemClifford A Hudis
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:2127-32. 2007.... - Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trialsJulie Lemieux
Unité de recherche en santé des populations, Centre des Maladies du Sein Deschênes Fabia, Hôpital St Sacrement, Quebec, Canada
J Clin Oncol 26:4458-65. 2008..Barriers to participation may relate to available protocols, physicians, and patients, but few data exist on barriers related to cancer care environments and protocol characteristics... - Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort studyMala Bahl
The Samuel Lunenfeld Research Institute and Department of Medicine, Mount Sinai Hospital, Toronto, ON, Canada
Breast Cancer Res Treat 94:135-44. 2005..Here, we examine whether serum levels of total cholesterol (TC) and triglycerides (TG) influence breast cancer outcome... - A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss
Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
N Engl J Med 349:1793-802. 2003..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy... - Diet and breast cancer: evidence that extremes in diet are associated with poor survivalPamela J Goodwin
Department of Medicine, Sam Lunenfeld Research Institute Mount Sinai Hospital, Toronto, Ontario, Canada
J Clin Oncol 21:2500-7. 2003..Because of a U-shaped association of body mass index (BMI) with survival in breast cancer, we hypothesized that a nonlinear association also existed for dietary variables... - American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant settingEric P Winer
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 21:2597-9. 2003 - Optimal chemotherapy for women with breast cancer: the plot thickensJoseph L Pater
J Clin Oncol 21:963-4. 2003 - The best use of adjuvant endocrine treatmentsKathleen I Pritchard
Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
Breast 12:497-508. 2003..Her-2 neu status is being explored as a predictive factor for selection of endocrine therapy, but is not yet considered standard for this purpose... - neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part IIKathleen I Pritchard
J Clin Oncol 21:399-400. 2003 - Endocrine therapy of advanced disease: analysis and implications of the existing dataKathleen I Pritchard
Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, M4N 3M5 Canada
Clin Cancer Res 9:460S-7S. 2003..The use of estrogen and progesterone receptor status to select for endocrine therapy is undeniably crucial. HER2/neu overexpression may also predict response to endocrine therapy, but this remains controversial... - Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?Kathleen I Pritchard
J Clin Oncol 20:4611-4. 2002 - Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomesPamela J Goodwin
Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Ontario, Canada
Breast Cancer Res Treat 74:65-76. 2002..The adverse effect of IGFBP-3 on distant recurrence in postmenopausal women with estrogen receptor positive breast cancer should be further investigated... - American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002Eric P Winer
Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
J Clin Oncol 20:3317-27. 2002..POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane... - Adjuvant therapy for early breast cancer: where do we stand today?Kathleen I Pritchard
Department of Medicine, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
MedGenMed 5:17. 2003 - The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancerShelley B Bull
Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
J Clin Oncol 22:86-96. 2004.... - Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort studyPamela J Goodwin
Department of Medicine, Division of Clinical Epidemiology at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario M5G 1X5, Canada
J Clin Oncol 20:42-51. 2002..Because of this and because of its recognized association with obesity, an adverse prognostic factor in breast cancer, we examined the prognostic associations of insulin in early-stage breast cancer... - A review of exemestane in the management of breast cancerNan Soon Wong
Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Ontario, Canada
Expert Opin Pharmacother 6:2353-63. 2005..In early breast cancer, key questions remain regarding the optimal sequence, duration and type of aromatase inhibitors, as well as their long-term safety... - Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss
Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
J Natl Cancer Inst 97:1262-71. 2005..This report presents updated findings from the trial... - Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?Pamela J Goodwin
Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
J Clin Oncol 23:6037-42. 2005..It has been suggested that leptin may mediate adverse prognostic effects of obesity in breast cancer... - Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5Wendy R Parulekar
National Cancer Institute of Canada Clinical Trials Group, Queens University, 10 Stuart St, Kingston, Ontario K7L3N6, Canada
J Clin Oncol 23:6002-8. 2005..To investigate the therapeutic impact of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer... - Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group TrMark N Levine
Department of Clinical Epidemiology, McMaster University, Hamilton, Ontario, Canada
J Clin Oncol 23:5166-70. 2005.... - Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifenKathleen I Pritchard
J Clin Oncol 23:4850-2. 2005 - Prognostic factors affecting the natural history of node-negative breast cancerMaureen E Trudeau
Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Breast Cancer Res Treat 89:35-45. 2005..We undertook a natural history investigation of a broad selection of prognostic factors in a cohort of women with node-negative breast cancer... - American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004Eric P Winer
Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
J Clin Oncol 23:619-29. 2005..To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors... - Estimating per patient funding for cancer clinical trials: an Ontario based surveyJames R Wright
Juravinski Cancer Center, Hamilton Health Sciences, 699 Concession St, Hamilton, Ontario, Canada, L8V 5C2
Contemp Clin Trials 26:421-9. 2005..These issues are likely not unique to oncology... - Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancerKathleen I Pritchard
Toronto Sunnybrook Regional Cancer and Department of Medicine, University of Toronto, Ont
CMAJ 166:1017-22. 2002..SPONSOR: The steering committee was convened by Health Canada. COMPLETION DATE: October 2001... - Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic reviewYolanda Madarnas
Cancer Centre of Southeastern Ontario, Kingston General Hospital, 25 King Street West, Kingston, ON, Canada K7L 5P9
Cancer Treat Rev 34:539-57. 2008.... - Should observational studies be a thing of the past?Kathleen I Pritchard
J Natl Cancer Inst 100:451-2. 2008 - Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variablesPamela J Goodwin
Mount Sinai Hospital, 1284 600 University Avenue, Toronto, Ontario M5G 1X4, Canada
J Clin Oncol 22:4184-92. 2004..Evidence that psychosocial status and health-related quality of life (HRQOL) are associated with breast cancer (BC) outcomes is weak and inconsistent. We examined prognostic effects of these factors in a prospective cohort study... - Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of lifeKathleen I Pritchard
Toronto Sunnybrook Regional Cancer Centre, Sunnybrook Health Sciences Centre and the University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
Eur J Cancer 43:1644-5. 2007 - HER-2 and topoisomerase II as predictors of response to chemotherapyKathleen I Pritchard
Sunnybrook Odette Cancer Centre, Department of Medicine, University of Toronto, 2075 Bayview Ave, Toronto, ON, Canada
J Clin Oncol 26:736-44. 2008..Additional studies will be required to clarify these relationships... - Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing dataLouise Bordeleau
Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5
J Clin Oncol 21:1944-51. 2003..To evaluate the effect of a standardized group psychosocial intervention on health-related quality of life (HrQOL) in women with metastatic breast cancer and to explore the effect of missing data in HrQOL analyses... - Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19Jianhua Liu
National Cancer Institute of Canada Clinical Trials Group, Cancer Research Institute, Queens University, 10 Stuart Street, K7L3N6, Kingston, Ontario, Canada
Breast Cancer Res Treat 100:263-71. 2006..Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL... - A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancerEileen Rakovitch
Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
Breast Cancer Res Treat 77:285-93. 2003..To assess how women with ductal carcinoma in situ (DCIS) perceive their risks of recurrence, dying from breast cancer, and psychological distress compared to women with early stage invasive breast cancer (EIBC)...